Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Edward Kavalerchik"'
Autor:
Paul Finnegan, Edward Kavalerchik, Bita Fakhri, Geoffrey Shouse, John Kimble Frazer, Sanjay K. Aggarwal, Annabel Kate Frank
Publikováno v:
Blood. 138:4899-4899
Introduction: High-dose chemotherapy and autologous hematopoietic cell transplant (HDT-AHCT) is considered a standard-of-care (SOC) consolidation therapy for patients with aggressive systemic non-Hodgkin (NHL) and Hodgkin lymphomas (HL). This therapy
Autor:
Bhagirathbhai Dholaria, Edward Kavalerchik, Attaphol Pawarode, Bita Fakhri, Geoffrey Shouse, Lihua E. Budde, Sanjay H. Aggarwal, Michael Scordo, Carolyn Mulroney, Sergio Giralt, Mehrdad Abedi, Muzaffar H. Qazilbash, Paul Finnegan
Publikováno v:
Transplantation and Cellular Therapy. 27:S26-S27
Autor:
Muzaffar H. Qazilbash, Lihua E. Budde, Sanjay K. Aggarwal, Mehrdad Abedi, Bita Fakhri, Carolyn Mulroney, Michael Scordo, Edward Kavalerchik, Attaphol Pawarode, Bhagirathbhai Dholaria, Paul Finnegan, Sergio Giralt
Publikováno v:
Blood. 136:14-15
Introduction: HDT-AHCT is a standard and potentially curative therapy for patients with high risk, chemosensitive lymphomas. Improvements in supportive care and HCT practices have led to increasing use of HDT-AHCT worldwide particularly in elderly an
Autor:
Ruben Niesvizky, Michael Wang, David S. Siegel, Edward Kavalerchik, Andrzej Jakubowiak, Sundar Jagannath, Ravi Vij, Mei Huang
Publikováno v:
Leukemia & Lymphoma. 56:2959-2961
In patients with relapsed and/or refractory multiple myeloma (MM), achievement of a deep response following anti-MM treatment has been associated with improved disease control, progression-free sur...
Publikováno v:
Journal of Clinical Oncology. 26:2911-2915
Although rare, chronic myeloid leukemia (CML) represents an important paradigm for understanding the molecular events leading to malignant transformation of primitive hematopoietic progenitors. CML was the first cancer to be associated with a defined
Autor:
Satwant Lally, Edward Kavalerchik, Laura Saunders, Tae H. Han, Sheila Bheddah, Scott J. Dylla
Publikováno v:
Journal of Clinical Oncology. 35:TPS2597-TPS2597
TPS2597 Background: Delta-like protein 3 (DLL3) is an inhibitory ligand of the Notch receptor family. It is highly expressed in high-grade neuroendocrine carcinoma (NEC), such as small cell lung cancer (SCLC) and large cell NEC (LCNEC), but is not ex
Autor:
Sheila Bheddah, Scott J. Dylla, Cristina Magi-Galluzzi, Amr Fergany, Paul Elson, Laura Saunders, Jesse K. McKenney, Kumiko Isse, Petros Grivas, Sky Watson, Brian I. Rini, Bonnie Shadrach, Vadim S. Koshkin, Karen Streator Smith, Andrew J. Stephenson, Jorge A. Garcia, Hamid Emamekhoo, Noah Theiss, Edward Kavalerchik
Publikováno v:
Journal of Clinical Oncology. 35:382-382
382 Background: SCBC is rare with limited data on treatment and outcomes. DLL3, a Notch pathway protein, is expressed in small cell lung cancer (SCLC) and neuroendocrine tumors. Phase I/II trials of the anti-DLL3 antibody-drug conjugate, rovalpituzum
Autor:
Ruben Niesvizky, William I. Bensinger, Michael Wang, Robert Z. Orlowski, David S. Siegel, Mei Huang, Edward Kavalerchik, Thomas Martin, Melissa Alsina
Publikováno v:
Blood. 122(18)
We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m2 days 1 and 2 of cycle 1 a
Autor:
Jason Gotlib, Edward Kavalerchik, John Hood, Chi Ching Mak, Ifat Geron, Ken Kaushansky, Ayalew Tefferi, Annelie Abrahamsson, Richard Soll, Charlene F. Barroga, Catriona Jamieson, Jeffrey Durocher, Glenn Noronha
Publikováno v:
Cancer Cell. 13(5)
SummaryPolycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In
Autor:
Sundar Jagannath, David S. Siegel, Michael Wang, Edward Kavalerchik, Mei Huang, Ruben Niesvizky, Ravi Vij, Andrzej Jakubowiak
Publikováno v:
Blood. 122:1965-1965
Introduction In patients (pts) receiving novel anti-multiple myeloma (MM) therapy, an early marker of response would be useful for predicting patient outcomes. Markers in blood with a short half-life, such as serum free light chain (sFLC), may have t